Meningioma
4
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 4 programs with unclassified modality
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Jazz PharmaceuticalsONC201
Eli Lilly and CompanyAbemaciclib
AstraZenecaAZD2014
Heron TherapeuticsB10 L-BPA Injection
Heidelberg PharmaCarbon Ion Radiotherapy
Clinical Trials (5)
Total enrollment: 135 patients across 5 trials
A Study of ONC201 for Refractory Meningioma
Start: Dec 2026Est. completion: Apr 20270
Phase 2Withdrawn
Abemaciclib in Newly Diagnosed Meningioma Patients
Start: Mar 2025Est. completion: Sep 203072 patients
Phase 2Recruiting
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
Start: Oct 2017Est. completion: Jul 202428 patients
Phase 2Unknown
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
Start: Oct 2024Est. completion: Dec 2026
Phase 1/2Active Not Recruiting
Carbon Ion Radiotherapy for Atypical Meningiomas
Start: Jun 2012Est. completion: Feb 202635 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 135 patients
5 companies competing in this space